Lundbeck eyes solid premium in Genmab field
Antibodies are hot in the international pharmaceutical industry, and they might also hold the key to unlocking certain doors within brain disorders, according to Lundbeck, which is in the midst of creating a platform aimed at the field.
by Leonora Beck
Several of the world’s many biotech and drug companies are chasing candidate drugs based on antibodies. The economic potential is huge, and the many successes within the field have made them all the rage.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab CEO expects profitable years ahead
For abonnenter
Bleak years ahead for Lundbeck
For abonnenter
Lundbeck: This is our focus for 2014 and 2015
For abonnenter
